Horizon Medical Products Will Relieve Debt Load With IPO Proceeds
This article was originally published in The Gray Sheet
Horizon Medical Products is earmarking the lion's share of $31.6 mil. in anticipated net proceeds from a planned initial public offering to settle outstanding debt related to the firm's July 15 acquisition of Pfizer's Strato/Infusaid business and its October 1995 purchase of NeoStar Medical Technologies.
You may also be interested in...
Asking whether FDA’s decision to allow emergency use of two old anti-malarial drugs was ‘political’ misses the point. The issue already was political, and FDA’s action may well be the best way to keep some measure of federal control on supplies of a drug with important other uses.
Guidelines for health care providers could help prevent shortages as demand for possible treatments surge, groups say. Stakeholders also argue “Buy America” executive order would hamper drug access.
BD and BioMedomics have released a new rapid point-of-care test that can detect antibodies in blood to confirm current or past exposure to COVID-19.